Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules
The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal transduction system, are long-established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a particularly high number of clinical trials involving PDE inhibi...
Saved in:
Main Authors: | Andrey D. Bondarev (Author), Misty M. Attwood (Author), Jörgen Jonsson (Author), Vladimir N. Chubarev (Author), Vadim V. Tarasov (Author), Wen Liu (Author), Helgi B. Schiöth (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recent developments of topoisomerase inhibitors: Clinical trials, emerging indications, novel molecules and global sales
by: Andrey D. Bondarev, et al.
Published: (2024) -
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
by: Amelia D. Dahlén, et al.
Published: (2022) -
Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials
by: Victoria A. Nazarova, et al.
Published: (2022) -
The international clinical trials registry platform (ICTRP): data integrity and the trends in clinical trials, diseases, and drugs
by: Eugenia D. Namiot, et al.
Published: (2023) -
Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review
by: Farzin Zobdeh, et al.
Published: (2022)